Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Large Cell 2Adenocarcinoma 2

Interventions

Carboplatin 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2Paclitaxel 2Docetaxel 2vandetanib 1tanespimycin 1Vinorelbine 1Temozolomide 1Pemetrexed 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Crizotinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Large Cell × alpha-2'-deoxythioguanosine × Clear all
NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Maia Biotechnology

Phase 2 Active not recruiting
227 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡